Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 9/20 | 0.55 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.33 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655865 | 0.92 | CSF1R (0.52) | CSF1RGRM2ACMSDSCN9AHDAC3 | |
| SCHEMBL5649481 | 0.87 | CSF1R (0.56) | CSF1RHDAC3HDAC1HDAC2 | |
| SCHEMBL5654003 | 0.85 | CSF1R (0.54) | CSF1RGRM2ACMSDSCN9A | |
| SCHEMBL3070902 | 0.85 | CSF1R (0.41) | CSF1RGRM2ACMSDSCN9AHDAC3 | |
| SCHEMBL3096483 | 0.85 | CSF1R (0.41) | CSF1RGRM2ACMSDSCN9A | |
| SCHEMBL5654118 | 0.85 | CSF1R (0.57) | CSF1RGRM2GAA | |
| Acetic Acid SCHEMBL5651425 | 0.82 | CSF1R (0.39) | CSF1RGRM2ACMSDSCN9ACLCN2 | |
| SCHEMBL3096496 | 0.82 | CSF1R (0.39) | CSF1RGRM2ACMSDSCN9AHDAC3 | |
| SCHEMBL5655868 | 0.77 | CSF1R (0.54) | CSF1RHDAC3HDAC1HDAC2 | |
| SCHEMBL3089553 | 0.76 | CSF1R (0.49) | CSF1RGRM2ACMSDSCN9ACAMK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452996-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| EP-2021329-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-13 | — | — | EP | disclosed |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-9221797-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-29 | — | — | US | disclosed |
| US-20140148448-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| US-8674100-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2014-03-18 | — | — | US | disclosed |
| EP-2687516-A1 | Inhibitors of C-FMS Kinase | Janssen Pharmaceutica N.V. (BE) | 2014-01-22 | — | — | EP | disclosed |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | CSF1R 58/4885GRM2 1679/4885ACMSD 4574/4885 |
| US-20140148448-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | CSF1R 58/4885GRM2 1679/4885ACMSD 4574/4885 |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | CSF1R 58/4885GRM2 1679/4885ACMSD 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.